Is It Time to Review How We Use Proteinuria to Define Disease Activity in Glomerular Diseases?
- 17 March 2026
- journal article
- Published by Wolters Kluwer Health in Journal of the American Society of Nephrology
- Vol. 37 (7) , 1564-1566
Abstract
An abstract is unavailable. This article is available as a PDF only.Keywords
This publication has 10 references indexed in Scilit:
- CKD progression, kidney failure, and mortality among US patients with IgA nephropathyNephrology Dialysis Transplantation, 2025
- Primary glomerular diseases and long‐term adverse health outcomes: A nationwide cohort studyJournal of Internal Medicine, 2024
- Long-Term Results from an Open-Label Extension Study of Atacicept for the Treatment of IgA NephropathyJournal of the American Society of Nephrology, 2024
- Urinary sC5b-9 is Better Linked to Albuminuria Than to Intrarenal Inflammation in Common Kidney DiseaseKidney International Reports, 2024
- Developing Therapies for C3 GlomerulopathyClinical Journal of the American Society of Nephrology, 2024
- Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trialThe Lancet, 2023
- Efficacy and safety of a targeted-release formulation of budesonide in patients with primary IgA nephropathy (NefIgArd): 2-year results from a randomised phase 3 trialThe Lancet, 2023
- Long-Term Outcomes in IgA NephropathyClinical Journal of the American Society of Nephrology, 2023
- Making a Case for the Anti-inflammatory Effects of ACE Inhibitors and Angiotensin II Receptor Blockers: Evidence From Randomized Controlled TrialsMayo Clinic Proceedings, 2022
- End-Stage Renal Disease and Mortality Outcomes Across Different Glomerulonephropathies in a Large Diverse US PopulationMayo Clinic Proceedings, 2018